Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aridis Acquires Kenta mAb Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aridis Acquires Kenta mAb Portfolio

Includes six anti-infectives

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aridis has entered an agreement with Kenta Biotech to acquire Kenta’s portfolio of anti-infective human monoclonal antibody (mAb) products and technologies. The portfolio includes six anti-infectives for the treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). Two candidates are in Phase IIa trials for acute pneumonia.
 
Aridis founder and president Eric Patzer said, “We are pleased to complete this transaction and build upon the substantial financial investment and remarkable progress that our colleagues at Kenta Biotech have achieved in creating a portfolio of innovative products.”
 
Kenta chief executive officer Franco Merckling said, “We are pleased to have identified Aridis as the ideal partner to further develop the Kenta technology and project pipeline which has been built over the last seven years. Aridis, a leading San Francisco-area biotech company specializing in novel anti-infectives, is poised to accelerate the development of our drug candidates in both the U.S. and Europe.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics